Cargando…
Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands
BACKGROUND: Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor‐positive. Only limited data are available on androgen deprivation therapy (ADT). METHODS: Patients with advanced androgen receptor‐positive salivary duct carcinoma treated with first‐line...
Autores principales: | Boon, Eline, van Boxtel, Wim, Buter, Jan, Baatenburg de Jong, Robert J., van Es, Robert J. J., Bel, Miranda, Fiets, Edward, Oosting, Sjoukje F., Slingerland, Marije, Hoeben, Ann, Tesselaar, Margot E. T., Jonker, Marianne A., Flucke, Uta E., van der Graaf, Winette T. A., van Herpen, Carla M. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838735/ https://www.ncbi.nlm.nih.gov/pubmed/29272069 http://dx.doi.org/10.1002/hed.25035 |
Ejemplares similares
-
Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults
por: Boon, Eline, et al.
Publicado: (2016) -
A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands
por: Boon, Eline, et al.
Publicado: (2018) -
Improving survival in salivary duct cancer with adjuvant androgen deprivation therapy
por: van Boxtel, Wim, et al.
Publicado: (2019) -
Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib‐randomized phase II study Commence
por: Ham, Janneke C., et al.
Publicado: (2020) -
Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients
por: van Boxtel, Wim, et al.
Publicado: (2019)